Experimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-12

  Nalca, Aysegul ^a   Livingston, Virginia A ^a   Garza, Nicole L ^a   Zumbrun, Elizabeth E ^a   Frick, Ondraya M ^a   Chapman, Jennifer L ^a   Hartings, Justin M ^a,b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b 539 Metropolitan Court   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; BIOCHEMISTRY; BLOOD CELL COUNT; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; EXPOSURE; FEMALE; FEVER; LYMPHADENOPATHY; MACACA; MALE; MONKEYPOX; MONKEYPOX VIRUS; MORTALITY; NONHUMAN; POLYMERASE CHAIN REACTION; SMALLPOX; VIRUS LOAD; VIRUS TRANSMISSION; AEROSOL; ANIMAL; DISEASE TRANSMISSION; HUMAN; MACACA FASCICULARIS; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRULENCE;

ANIMALIA; MACACA; MACACA FASCICULARIS; MONKEYPOX VIRUS; VARIOLA VIRUS;

AEROSOLS; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MONKEYPOX; MONKEYPOX VIRUS; SMALLPOX; VIRULENCE;

EID: 77958496255     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012880     Document Type: Article

References (38)

1. Shchelkunov SN, Totmenin AV, Babkin IV, Safronov PF, Ryazankina OI, et al. (2001) Human monkeypox and smallpox viruses: genomic comparison. FEBS Lett 509: 66-70.
2. Parker S, Nuara A, Buller RM, Schultz DA (2007) Human monkeypox: an emerging zoonotic disease. Future Microbiol 2: 17-34.
3. Nalca A, Rimoin AW, Bavari S, Whitehouse CA (2005) Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 41: 1765-1771.
4. Jezek Z, Fenner F (1988) Human monkeypox. Basel; New York: Karger.
5. Fine PE, Jezek Z, Grab B, Dixon H (1988) The transmission potential of monkeypox virus in human populations. Int J Epidemiol 17: 643-650.
6. Marriott KA, Parkinson CV, Morefield SI, Davenport R, Nichols R, et al. (2008) Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 26: 581-588.
7. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, et al. (2004) Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428: 182-185.
8. Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, et al. (2008) Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A 105: 10889-10894.
9. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, et al. (2005) Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11: 740-747.
10. Handley L, Buller RM, Frey SE, Bellone C, Parker S (2009) The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. Expert Rev Vaccines 8: 841-850.
11. Nigam P, Earl PL, Americo JL, Sharma S, Wyatt LS, et al. (2007) DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology 366: 73-83.
12. Garza NL, Hatkin JM, Livingston V, Nichols DK, Chaplin PJ, et al. (2009) Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine 27: 5496-5504.
13. Food and Drug Administration H (2002) New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. 21 CFR Parts 314 and 601.
14. Kramski M, Matz-Rensing K, Stahl-Hennig C, Kaup FJ, Nitsche A, et al. A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection. PLoS One 5: e10412.
15. Adams MM, Rice AD, Moyer RW (2007) Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J Virol 81: 11084-11095.
16. Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, et al. (2009) Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother 53: 2620-2625.
17. Hutson CL, Olson VA, Carroll DS, Abel JA, Hughes CM, et al. (2009) A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J Gen Virol 90: 323-333.
18. Schriewer J, Buller RM, Owens G (2004) Mouse models for studying orthopoxvirus respiratory infections. Methods Mol Biol 269: 289-308.
19. Smee DF (2008) Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother 19: 115-124.
20. Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, et al. (2006) Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439: 745-748.
21. Tesh RB, Watts DM, Sbrana E, Siirin M, Popov VL, et al. (2004) Experimental infection of ground squirrels (Spermophilus tridecemlineatus) with monkeypox virus. Emerg Infect Dis 10: 1563-1567.
22. Henderson DA (2009) Smallpox: the death of a disease: the inside story of eradicating a worldwide killer. Amherst, N.Y.: Prometheus Books.
23. Swearengen JR (2006) Biodefense: research methodology and animal models. Boca Raton: CRC Taylor & Francis.
24. Jahrling PB, Hensley LE, Martinez MJ, Leduc JW, Rubins KH, et al. (2004) Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A 101: 15196-15200.
25. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L (2001) The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest 81: 1581-1600.
26. Besch TK, Ruble DL, Gibbs PH, Pitt ML (1996) Steady-state minute volume determination by body-only plethysmography in juvenile rhesus monkeys. Lab Anim Sci 46: 539-544.
27. Hartings JM, Roy CJ (2004) The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates. J Pharmacol Toxicol Methods 49: 39-55.
28. Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, et al. (2008) Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res 79: 121-127.
29. Prophet EB, Mills B, Arrington JB, Sobin LH (1992) Laboratory Methods for Histotechnology. Washington, D.C.: Armed Forces Institute of Pathology.
30. Bauer KD, de la Torre-Bueno J, Diel IJ, Hawes D, Decker WJ, et al. (2000) Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 6: 3552-3559.
31. Reynolds MG, Yorita KL, Kuehnert MJ, Davidson WB, Huhn GD, et al. (2006) Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis 194: 773-780.
32. Hahon N (1961) Smallpox and related poxvirus infections in the simian host. Bacteriol Rev 25: 459-476.
33. Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, et al. (2009) ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother 53: 1817-1822.
34. Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, et al. (2005) Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 79: 7845-7851.
35. Rimoin AW, Kisalu N, Kebela-Ilunga B, Mukaba T, Wright LL, et al. (2007) Endemic human monkeypox, Democratic Republic of Congo, 2001-2004. Emerg Infect Dis 13: 934-937.
36. Hutin YJ, Williams RJ, Malfait P, Pebody R, Loparev VN, et al. (2001) Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis 7: 434-438.
37. Hahon N, Mc GM (1961) Air-borne infectivity of the variola-vaccinia group of poxviruses for the cynomolgus monkey, Macaca irus. J Infect Dis 109: 294-298.
38. Huhn GD, Bauer AM, Yorita K, Graham MB, Sejvar J, et al. (2005) Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis 41: 1742-1751.